# |
PMID |
Sentence |
1 |
16374431
|
Using double-staining procedures, localization of the HIF target geneproducts vascular endothelial growth factor (VEGF) and endoglin was studied in relation to HIFalpha.
|
2 |
16374431
|
The HIF-target gene VEGF colocalized with HIF-1alpha protein in glomeruli and medullary collecting ducts.
|
3 |
16374431
|
HIF-2alpha colocalized with the endothelium-associated angiogenic factor, endoglin.
|
4 |
16374431
|
HIF-1alpha seems to be primarily involved in tubulogenesis and HIF-2alpha in renal vasculogenesis.
|
5 |
16374431
|
Using double-staining procedures, localization of the HIF target geneproducts vascular endothelial growth factor (VEGF) and endoglin was studied in relation to HIFalpha.
|
6 |
16374431
|
The HIF-target gene VEGF colocalized with HIF-1alpha protein in glomeruli and medullary collecting ducts.
|
7 |
16374431
|
HIF-2alpha colocalized with the endothelium-associated angiogenic factor, endoglin.
|
8 |
16374431
|
HIF-1alpha seems to be primarily involved in tubulogenesis and HIF-2alpha in renal vasculogenesis.
|
9 |
22610571
|
We recently found that human glomeruli deprived of the Bowman's capsule contain a population of CD133(-)CD146(+) cells that coexpress the typical mesenchymal stem cells (MSCs) markers (such as CD29, CD105, and CD73) and renal specific stem cell markers (such us CD24 and Pax2).
|
10 |
23529165
|
Blood samples were analyzed for angiogenic markers, including placental growth factor, the soluble receptor fms-like tyrosine kinase receptor-1 for vascular endothelial growth factor, and endoglin.
|
11 |
23928393
|
The angiogenic markers including soluble fms-like tyrosine kinase 1, placental growth factor, and soluble endoglin have demonstrated to be the most promising, perhaps in conjunction with traditional markers such as plasma protein-13 and uterine artery Doppler studies.
|
12 |
26646071
|
Analysis of different endoglin mutants, allowed the mapping of the endoglin RGD motif as involved in the adhesion process.
|
13 |
29660398
|
We performed an immunohistochemical study using a panel of endothelial, myoid, mesenchymal and stem/progenitor markers, namely CD31, CD34, CD105 (endoglin), CD117/c-kit, nestin, desmin, α-smooth muscle actin (α-SMA) and the heavy chain of smooth muscle myosin (SMM).
|
14 |
29660398
|
The capsular SC/TCs had a strong CD34 and partial nestin and CD105 immunopositivity.
|
15 |
29660398
|
Subcapsular and interstitial SC/TCs expressed c-kit, nestin, CD105, but also α-SMA and SMM, therefore having a myoid phenotype.
|
16 |
29660398
|
The endothelial SC/TCs phenotype was CD31+/CD34+/CD105+/nestin±/SMM±/α-SMA±.
|
17 |
29660398
|
In epithelial cells, we found a positive expression for CD31, CD117/c-kit, desmin, CD34, SMM, and CD105.
|
18 |
29660398
|
We performed an immunohistochemical study using a panel of endothelial, myoid, mesenchymal and stem/progenitor markers, namely CD31, CD34, CD105 (endoglin), CD117/c-kit, nestin, desmin, α-smooth muscle actin (α-SMA) and the heavy chain of smooth muscle myosin (SMM).
|
19 |
29660398
|
The capsular SC/TCs had a strong CD34 and partial nestin and CD105 immunopositivity.
|
20 |
29660398
|
Subcapsular and interstitial SC/TCs expressed c-kit, nestin, CD105, but also α-SMA and SMM, therefore having a myoid phenotype.
|
21 |
29660398
|
The endothelial SC/TCs phenotype was CD31+/CD34+/CD105+/nestin±/SMM±/α-SMA±.
|
22 |
29660398
|
In epithelial cells, we found a positive expression for CD31, CD117/c-kit, desmin, CD34, SMM, and CD105.
|
23 |
29660398
|
We performed an immunohistochemical study using a panel of endothelial, myoid, mesenchymal and stem/progenitor markers, namely CD31, CD34, CD105 (endoglin), CD117/c-kit, nestin, desmin, α-smooth muscle actin (α-SMA) and the heavy chain of smooth muscle myosin (SMM).
|
24 |
29660398
|
The capsular SC/TCs had a strong CD34 and partial nestin and CD105 immunopositivity.
|
25 |
29660398
|
Subcapsular and interstitial SC/TCs expressed c-kit, nestin, CD105, but also α-SMA and SMM, therefore having a myoid phenotype.
|
26 |
29660398
|
The endothelial SC/TCs phenotype was CD31+/CD34+/CD105+/nestin±/SMM±/α-SMA±.
|
27 |
29660398
|
In epithelial cells, we found a positive expression for CD31, CD117/c-kit, desmin, CD34, SMM, and CD105.
|
28 |
29660398
|
We performed an immunohistochemical study using a panel of endothelial, myoid, mesenchymal and stem/progenitor markers, namely CD31, CD34, CD105 (endoglin), CD117/c-kit, nestin, desmin, α-smooth muscle actin (α-SMA) and the heavy chain of smooth muscle myosin (SMM).
|
29 |
29660398
|
The capsular SC/TCs had a strong CD34 and partial nestin and CD105 immunopositivity.
|
30 |
29660398
|
Subcapsular and interstitial SC/TCs expressed c-kit, nestin, CD105, but also α-SMA and SMM, therefore having a myoid phenotype.
|
31 |
29660398
|
The endothelial SC/TCs phenotype was CD31+/CD34+/CD105+/nestin±/SMM±/α-SMA±.
|
32 |
29660398
|
In epithelial cells, we found a positive expression for CD31, CD117/c-kit, desmin, CD34, SMM, and CD105.
|
33 |
29660398
|
We performed an immunohistochemical study using a panel of endothelial, myoid, mesenchymal and stem/progenitor markers, namely CD31, CD34, CD105 (endoglin), CD117/c-kit, nestin, desmin, α-smooth muscle actin (α-SMA) and the heavy chain of smooth muscle myosin (SMM).
|
34 |
29660398
|
The capsular SC/TCs had a strong CD34 and partial nestin and CD105 immunopositivity.
|
35 |
29660398
|
Subcapsular and interstitial SC/TCs expressed c-kit, nestin, CD105, but also α-SMA and SMM, therefore having a myoid phenotype.
|
36 |
29660398
|
The endothelial SC/TCs phenotype was CD31+/CD34+/CD105+/nestin±/SMM±/α-SMA±.
|
37 |
29660398
|
In epithelial cells, we found a positive expression for CD31, CD117/c-kit, desmin, CD34, SMM, and CD105.
|
38 |
31191670
|
Furthermore, these cells express the typical MSC markers CD73, CD90, and CD105.
|
39 |
31191670
|
Immunofluorescence-based stainings of sectioned 3D-NPCs revealed cells expressing the renal progenitor cell markers (SIX2 and PAX8), podocyte markers (Nephrin and Podocin), the endothelial marker (CD31), and mesenchymal markers (Vimentin and PDGFR-β).
|